GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Brainstorm Cell
Brainstorm Cell is a biotech company developing cell therapies for neurodegenerative diseases. Its price chart is a dramatic story of the hopes surrounding its ALS therapy and subsequent disappointment due to mixed research results.
Share prices of companies in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing stem cell-based therapies for the treatment of neurodegenerative diseases. We've categorized it under the "Neurology" category. The chart below shows how investors view this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Brainstorm Cell is an Israeli biotech company developing cell therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As a component of the GURU.Markets index, it is at the forefront of science. The chart below is for the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
BCLI - Daily change in the company's share price Brainstorm Cell
Brainstorm Cell Therapeutics' daily price change reflects the extreme volatility inherent in cell therapy companies. This metric measures its sensitivity to clinical trial data for its ALS treatments.
Daily change in the price of a set of shares in a market segment - Neuro
Brainstorm Cell Therapeutics develops cell therapies to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This is a cutting-edge and risky area of biotech. The chart below illustrates the high volatility typical of this sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Brainstorm Cell is an Israeli biotech company developing cell therapies for the treatment of neurodegenerative diseases. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Brainstorm Cell
Brainstorm Cell Therapeutics' year-to-date performance is the story of its years-long battle to secure approval for its cell therapy for ALS. Its 12-month market cap is entirely dependent on FDA decisions. Its valuation reflects the hopes of patients and investors that its unique approach can offer new hope for this devastating disease.
Annual dynamics of market capitalization of the market segment - Neuro
Brainstorm Cell Therapeutics Inc. is an Israeli biotech company developing cell therapies for the treatment of neurodegenerative diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Brainstorm Cell Therapeutics, a biotech company developing cell therapies for neurodegenerative diseases such as ALS, operates at the forefront of science. Its year-over-year market capitalization reflects the hopes of patients and investors for a breakthrough in treating these devastating diseases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Brainstorm Cell
Brainstorm is an Israeli biotech company developing cell therapies for neurodegenerative diseases. Its monthly performance is entirely dependent on the results of its clinical trials and its interactions with the FDA regarding its ALS drug.
Monthly dynamics of market capitalization of the market segment - Neuro
Brainstorm Cell Therapeutics develops cell therapies to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This is one of the most complex areas in biotech. The chart below reflects the hopes and disappointments of investors monitoring the results of clinical trials in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Brainstorm Cell is an Israeli biotech company developing cell therapies for neurodegenerative diseases. Its shares represent a high-risk bet on the success of its lead drug. Its performance depends entirely on regulatory decisions (FDA) and clinical trial data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Brainstorm Cell
Shares of Brainstorm Cell, an Israeli company developing cell therapies for neurodegenerative diseases, are extremely volatile. Weekly price movements are entirely dependent on news about the progress of clinical trials, particularly in the treatment of ALS. The chart below visualizes how hopes and disappointments in this complex field of medicine influence the stock's price.
Weekly dynamics of market capitalization of the market segment - Neuro
Brainstorm Cell Therapeutics is developing cell therapy for neurodegenerative diseases like ALS. It's an area of great hope and disappointment. This chart illustrates how clinical trial results can trigger extreme stock price movements unrelated to the market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Brainstorm Cell is a biotech company focused on cell therapy. This chart shows how out of sync its weekly performance is with the broader market. Its stock price is driven by news about clinical trials and scientific progress, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
BCLI - Market capitalization of the company Brainstorm Cell
Brainstorm Cell Therapeutics' stock price reflects years of hope and disappointment surrounding its cell therapy for ALS. The company's market cap is extremely sensitive to regulatory decisions. Its dynamics illustrate the difficult and emotionally charged path to defeating this devastating disease.
BCLI - Share of the company's market capitalization Brainstorm Cell within the market segment - Neuro
Brainstorm Cell's stake in the neuroscience sector represents a multi-year bet on its cell therapy for ALS and other neurodegenerative diseases. Its market share reflects the hopes of patients and investors that its innovative stem cell-based approach will prove successful.
Market capitalization of the market segment - Neuro
Here's a chart of the total market capitalization of biotech companies developing cell therapies for neurological diseases. Brainstorm Cell Therapeutics is one of the pioneers. The graph shows how the market values this cutting-edge, yet high-risk, technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with amyotrophic lateral sclerosis (ALS). Brainstorm Cell Therapeutics' market cap reflects investors' faith in its stem cell therapy. The line depicts the roller coaster of hopes and disappointments in the fight for a stake in the future of neuroscience.
Book value capitalization of the company, segment and market as a whole
BCLI - Book value capitalization of the company Brainstorm Cell
Brainstorm Cell Therapeutics' book value represents its scientific and production capital. The chart below reflects the valuation of its patents for the NurOwn® cell therapy platform for treating neurodegenerative diseases. The pipeline's growth reflects investments in the development of this innovative approach.
BCLI - Share of the company's book capitalization Brainstorm Cell within the market segment - Neuro
Brainstorm Cell's core assets are its manufacturing facilities, certified to produce NurOwn cell therapy for the treatment of neurodegenerative diseases. The chart shows the company's share of this advanced and sophisticated biotech infrastructure.
Market segment balance sheet capitalization - Neuro
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Brainstorm Cell, a cell therapy developer, has a more streamlined model. But it is building its own facilities to produce its complex drugs.
Book value of all companies included in the broad market index - GURU.Markets
Brainstorm Cell Therapeutics develops cell therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis. The company's assets include unique laboratories where stem cells are "converted" into medicine. The chart below shows the financial impact of this promise for patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Brainstorm Cell
Brainstorm Cell Therapeutics is a biotech company developing cell therapy for neurodegenerative diseases such as ALS. Its value lies in its scientific platform. The chart below is a story of hope for patients and investors, with momentum entirely dependent on regulatory decisions and research data.
Market to book capitalization ratio in a market segment - Neuro
Brainstorm Cell Therapeutics Inc. is a biotech company developing cell therapies for the treatment of neurodegenerative diseases. Its value is based on the potential of its technology. This chart shows how its market valuation, reflecting its hopes for a medical breakthrough, is a multiple of its current assets.
Market to book capitalization ratio for the market as a whole
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. Their market valuation, as shown in this chart, is based on the high hopes for their NurOwn platform, despite the complex regulatory landscape.
Debts of the company, segment and market as a whole
BCLI - Company debts Brainstorm Cell
Brainstorm Cell Therapeutics, a cell therapy company, is using raised capital to seek approval for its ALS drug. This chart tells the story of the company's long and difficult battle with regulators, which requires ongoing funding for additional research.
Market segment debts - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases such as ALS. This chart shows how its leverage reflects the long and arduous path to clinical development, including setbacks and the need to raise new capital to continue its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Brainstorm Cell
Brightcove provides a cloud-based platform for online video. Competition in this market from tech giants is fierce. This chart shows how the company is leveraging its capital to innovate and maintain its niche in the rapidly changing world of digital video.
Market segment debt to market segment book capitalization - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart compares its debt load to the overall market capitalization of the sector. It shows how the company finances its complex clinical trials.
Debt to book value of all companies in the market
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases such as ALS. This is one of the most complex areas in medicine. This graph of total market debt shows the overall risk appetite, which directly impacts the company's ability to fund its very expensive and risky clinical trials.
P/E of the company, segment and market as a whole
P/E - Brainstorm Cell
For Brainstorm Cell, a biotech company working on cell therapy for neurodegenerative diseases, the P/E ratio is not applicable. The company has no profit. Its valuation is a bet on the success of its clinical trials, a high-risk proposition.
P/E of the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the average valuation for the neuroscience sector, reflecting investor hopes for a breakthrough in cell therapy for these debilitating conditions.
P/E of the market as a whole
Brainstorm Cell Therapeutics is an Israeli biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This risk appetite chart helps understand how investors evaluate cutting-edge cell therapies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Brainstorm Cell
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based cell therapy for the treatment of neurodegenerative diseases. This chart reflects investor expectations for a breakthrough in the treatment of ALS. Future profits are dependent on regulatory approval.
%20P%2FE%20Brainstorm%20Cell&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Brainstorm-Cell&v=1772550792454 "Chart of the company's future (projected) P/E Brainstorm Cell")
Future (projected) P/E of the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases such as ALS. This chart reflects investor hopes and disappointments. It shows how the market views the prospects of its technology after a challenging regulatory journey.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772550792494 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases such as ALS. Its future depends on the results of clinical trials. The overall market optimism shown by this chart is critical to attracting the investment needed to advance such complex and expensive therapies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772550792628 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Brainstorm Cell
Brainstorm Cell Therapeutics is a late-stage biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. Its financial activities are focused on obtaining regulatory approval. This chart shows the costs associated with preparing for a potential commercial launch.
Profit of companies in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases. This chart, showing overall sector profitability, reflects the hopes surrounding cell therapy. The success or failure of Brainstorm's clinical trials has a profound impact on investor sentiment across the industry.
Overall market profit
Brainstorm Cell Therapeutics is a biotechnology company developing cell therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Their approach is based on the use of a patient's own stem cells.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Brainstorm Cell
Brainstorm Cell Therapeutics develops cell therapies for the treatment of neurodegenerative diseases such as ALS. Future revenue projections are speculative and depend on clinical trial results and regulatory approval.
%20profit%20of%20the%20company%20Brainstorm%20Cell&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Brainstorm-Cell&v=1772550792735 "Graph of future (projected) profit of the company Brainstorm Cell")
Future (predicted) profit of companies in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases. This chart shows overall revenue forecasts for the neuroscience segment. It reflects analysts' expectations for breakthroughs in cell therapy and how the company's technologies might fit into them.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772550792788 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases. Its success depends entirely on the results of clinical trials. This chart, reflecting investor sentiment, is critically important, as it determines the availability of capital to fund very expensive and long-term research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772550792850 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Brainstorm Cell
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. This chart, plotting market capitalization against missing revenue, reflects the company's long and arduous journey. Its dynamics show the rise and fall of investor hopes depending on the results of clinical trials.
P/S market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects the market's willingness to pay for cell therapy revenue, demonstrating confidence in Brainstorm's scientific platform and treatment potential.
P/S of the market as a whole
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart, which displays the average valuation, shows how much the biotech company's valuation depends on its future potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Brainstorm Cell
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases. This chart shows the market's estimate of its potential future revenue. It reflects investor confidence in the success of its clinical programs, particularly in the treatment of amyotrophic lateral sclerosis (ALS).
%20P%2FS%20Brainstorm%20Cell&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Brainstorm-Cell&v=1772550793102 "The graph of the company's future (projected) P/S Brainstorm Cell")
Future (projected) P/S of the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as ALS. The chart shows the average future sales estimate for the neuroscience sector. It helps understand how investors view the company's technology prospects following challenging clinical trial results.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772550793128 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Brainstorm Cell Therapeutics (BCLI) is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. Their future depends solely on the success of clinical trials. This graph of general economic expectations bears no relation to their scientific developments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772550793267 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Brainstorm Cell
Brainstorm Cell Therapeutics is a late-stage biotech company developing cell therapies for neurodegenerative diseases. It has no sales revenue. Its financial history is one of investing in breakthrough research. The graph will reflect future revenue from the commercialization of its therapy after approval.
Sales of companies in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As a late-stage company, its future revenue is entirely dependent on regulatory approval for its innovative treatment.
Overall market sales
Brainstorm Cell Therapeutics Inc. is a biotech company developing cell therapies for the treatment of neurodegenerative diseases. Its success depends entirely on the results of clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in biotech and the ability to attract capital to fund expensive R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Brainstorm Cell
Brainstorm Cell Therapeutics develops cell therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects analysts' long-term expectations for its innovative NurOwn platform.
%20sales%20of%20the%20company%20Brainstorm%20Cell&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Brainstorm-Cell&v=1772550793484 "Schedule of future (projected) sales of the company Brainstorm Cell")
Future (projected) sales of companies in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing autologous stem cell-based cell therapies for the treatment of neurodegenerative diseases. This chart shows the outlook for the neuroscience sector, reflecting hopes for breakthroughs in the treatment of diseases such as amyotrophic lateral sclerosis (ALS).
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772550793519 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for BrainStorm Cell Therapeutics. The company develops cell therapies for the treatment of neurodegenerative diseases. Its ability to fund expensive research is directly dependent on the influx of capital into the industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772550793532 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Brainstorm Cell
Brainstorm Cell Therapeutics is a late-stage biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. This chart reflects its investment in clinical research. Future profitability depends on regulatory approval and the commercial launch of its innovative treatment.
Market segment marginality - Neuro
Brainstorm Cell Therapeutics is a biopharmaceutical company developing autologous stem cell-based therapies for the treatment of neurodegenerative diseases such as ALS. Profitability depends on the success of its innovative platform. This chart shows the average profitability in the pharmaceutical industry, providing context for assessing the potential of its developments.
Market marginality as a whole
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for neurodegenerative diseases. Its future depends entirely on the results of clinical trials. This chart reflects the overall risk appetite of investors, which is critical to raising the capital needed to conduct research in such a complex and long-term field.
Employees in the company, segment and market as a whole
Number of employees in the company Brainstorm Cell
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. This chart reflects the size of the research and clinical teams. Progress on the chart may reflect key clinical trial milestones and regulatory engagements, which shape the company's future.
Share of the company's employees Brainstorm Cell within the market segment - Neuro
Brainstorm Cell Therapeutics develops cell therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows the company's share of the total number of scientists working in this complex field. It reflects its long-standing efforts and patients' hopes for a breakthrough.
Number of employees in the market segment - Neuro
Brainstorm Cell Therapeutics is a biopharmaceutical company developing autologous cell therapies for the treatment of neurodegenerative diseases. This chart, showing employment in the neuroscience sector, is important. The growing number of scientists in the field of cell therapy indicates the search for breakthrough treatments for complex diseases such as amyotrophic lateral sclerosis (ALS).
Number of employees in the market as a whole
Brainstorm Cell Therapeutics is developing cell therapies for the treatment of neurodegenerative diseases. This overall employment chart reflects the economic stability necessary to fund breakthrough medicine. Only in a healthy economy are investors and governments willing to invest significant resources in research that could lead to treatments for ALS and other serious diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Brainstorm Cell (BCLI)
Brainstorm Cell (BCLI) is an Israeli biotech company developing stem cell-based therapies for the treatment of neurodegenerative diseases (ALS). This is pure R&D, "intellectual capital." Its market value comes from faith in its scientific platform (NurOwn), not its staff.
%20of%20the%20company%20Brainstorm%20Cell%20(BCLI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Brainstorm-Cell-BCLI&v=1772550793964 "Chart of market capitalization per employee (in thousands of dollars) of the company Brainstorm Cell (BCLI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases. Its valuation is entirely dependent on the success of clinical trials. This chart clearly illustrates that in biotech, the market values the scientific potential that can be achieved by a small group of dedicated scientists.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772550794051 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Brainstorm Cell Therapeutics develops cell therapies for neurodegenerative diseases such as ALS. This is a cutting-edge field in medicine. This chart shows the extremely high valuation per employee, as the market cap reflects the hope that the technology being developed by a small scientific team will be able to treat previously incurable diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772550794149 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Brainstorm Cell (BCLI)
Brainstorm Cell is an Israeli biotech company developing cell therapy (NuOwn) for the treatment of neurodegenerative diseases, particularly ALS. This R&D is complex and expensive. This chart shows the company's "burn rate": how much the company spends (negative profit) on each scientist in this long battle for therapy approval.
%20Chart%20Brainstorm%20Cell%20(BCLI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Brainstorm-Cell-BCLI&v=1772550794250 "Company Profit Per Employee (in thousands of dollars) Chart Brainstorm Cell (BCLI)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative diseases such as ALS. While in clinical trials, the company incurs significant expenses. This chart helps evaluate the effectiveness of managing these costs while waiting for life-changing results for patients.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772550794333 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Brainstorm Cell (BCLI) is an Israeli biotech company developing a cell therapy (NurOwn) for the treatment of neurodegenerative diseases (ALS). It is a late-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist working in the complex field of cell therapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772550794357 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Brainstorm Cell (BCLI)
Brainstorm Cell Therapeutics is developing cell therapies for the treatment of neurodegenerative diseases such as ALS. Being in late-stage clinical trials, the company has no sales revenue yet. This graph is important as a starting point for assessing the company's enormous market potential.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Brainstorm-Cell-BCLI&v=1772550794401 "Sales chart per company employee Brainstorm Cell (BCLI)")
Sales per employee in the market segment - Neuro
Brainstorm Cell is a biotech R&D company developing cell therapy (NurOwn) for the treatment of neurodegenerative diseases such as ALS. This is an R&D business. This chart clearly shows that the company has no commercial revenue. The productivity of their scientific team is measured solely by progress in clinical trials.
Sales per employee for the market as a whole
FinVolution Group (FINV) is a China-based fintech platform that connects borrowers (small businesses and individuals) with financial institutions (lenders). It is a technological intermediary. This chart shows the fintech platform's performance. FinVolution bears no credit risk, but earns revenue from service fees using data analysis and AI for scoring. This allows them to process billions of transactions.
Short shares by company, segment and market as a whole
Shares shorted by company Brainstorm Cell (BCLI)
Brainstorm Cell (BCLI) is an Israeli biotech company that has been unsuccessfully seeking approval for its cell therapy for ALS for years. This chart shows the number of short positions. The bears are betting that the company has no chance after yet another FDA rejection.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Brainstorm-Cell-BCLI&v=1772550794605 "Short Shares Chart for the Company Brainstorm Cell (BCLI)")
Shares shorted by market segment - Neuro
Brainstorm Cell (BCLI) is a biotech company developing cell therapy (NurOwn) for the treatment of neurodegenerative diseases such as ALS. The chart below shows the overall short position in the CNS biotech sector. It demonstrates the lack of confidence among investors in the success of complex and lengthy clinical trials.
Shares shorted by the overall market
Brainstorm Cell (BCLI) operates in the riskiest area—cell therapy for neurological diseases. This chart measures the overall level of fear. When pessimism increases, investors immediately "exit risk." They sell off unprofitable biotech stocks, fearing that the R&D cash will run out before they achieve results.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Brainstorm Cell (BCLI)
Brainstorm Cell (BCLI) is developing NurOwn, a cell therapy for neurodegenerative diseases such as ALS. Biotech stocks at this stage are riding high on hopes of approval. This oscillator measures the strength of this sentiment. It shows when investor enthusiasm (above 70) or disappointment (below 30) about the clinical data peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Brainstorm-Cell-BCLI&v=1772550794828 "RSI 14 indicator chart for the company's stock Brainstorm Cell (BCLI)")
RSI 14 Market Segment - Neuro
Brainstorm Cell Therapeutics is a biotech company developing cell therapy (NurOwn) for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis). This chart shows the collective momentum across the entire neuroscience biotech niche. It helps determine whether the entire sector is overheated by expectations of a breakthrough or oversold by unsuccessful trials.
RSI 14 for the overall market
For Brainstorm Cell, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCLI (Brainstorm Cell)
Brainstorm Cell is developing a therapy based on patient-derived stem cells (NurOwn) for the treatment of neurodegenerative diseases such as ALS. This chart shows the analysts' average 12-month forecast, representing their collective bet that this sophisticated R&D platform will receive FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCLI-Brainstorm-Cell&v=1772550795006 "A chart showing analyst consensus forecasts for the expected stock price. BCLI (Brainstorm Cell)")
The difference between the consensus estimate and the actual stock price BCLI (Brainstorm Cell)
Brainstorm Cell (BCLI) is an Israeli biotech company whose fortunes are tied to NurOwn, a cell therapy for ALS (Lou Gehrig's disease). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith (or skepticism) in this sophisticated R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCLI-Brainstorm-Cell&v=1772550795126 "A chart showing the difference between the consensus forecast and the actual stock price. BCLI (Brainstorm Cell)")
Analyst consensus forecast for stock prices by market segment - Neuro
Brainstorm Cell (BCLI) is an Israeli biotech company developing cell therapy (NurOwn) for the treatment of neurodegenerative diseases such as ALS. This chart shows general expectations for the neuroscience sector. It reflects whether experts believe in a breakthrough in R&D for ALS treatment or consider the sector a "graveyard."
Analysts' consensus forecast for the overall market share price
Brainstorm Cell (BCLI) is an Israeli biotech company attacking ALS (Lou Gehrig's disease). They are developing a cell therapy (NurOwn) based on a patient's own stem cells. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D projects in one of the most complex and risky areas of neuroscience.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Brainstorm Cell
Brainstorm is a champion in stem cell R&D. Their entire fate is tied to a single product (NurOwn)—a personalized cell therapy they've been trying for years to get FDA approval for ALS (Lou Gehrig's disease). This chart is a summary of their battle with the FDA. It reflects their (controversial) clinical data and their (desperate) fight for approval.
AKIMA Market Segment Index - Neuro
Brainstorm Cell is a cell therapy company working on treating neurodegenerative diseases like ALS (amyotrophic lateral sclerosis). They use patients' own cells. This chart compares their composite index to the sector, showing how their neurotechnology stacks up against others.
The AKIM Index for the overall market
BrainStorm Cell Therapeutics is a biotech company developing a cell therapy (NurOwn) for the treatment of ALS. It is battling regulators. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop important to this controversial scientific story.
